Anticancer nucleosides phosphorylation

Human deoxycytidine kinase enzyme has a broad substrate specificity and provides the phosphorylation of purine/pyrimidine deoxynucleosides and pyrimidine ribonucleosides. Deoxycytidine kinase is critical for phosphorylation of cytidine analogs and provides first steps of activation of highly effective anti-cancer prodrugs, such as aracytidine, gemcitabine and cladribine.

PRECICE® dCK Phosphorylation Assay Kit is a first tool for rapid evaluation of substrates properties of novel nucleoside analogues for human deoxycytidine kinase.

Principle

PRECICE® dCK Phosphorylation Assay Kit is based on competitive inhibition of deoxyinosine (dIR) phosphorylation by dCK enzyme. In the absence of nucleoside competitor, deoxycytidine kinase phosphorylates deoxyinosine resulting in the formation of dIMP. dIMP is further oxidized by IMPDH to dXMP and NADH2 continuously monitored at 340nm. In the presence of nucleoside competitor, the phosphorylation of deoxyinosine, poor dCK substrate, is inhibited detected as a decrease in NADH2 formation.

PRECICE® dCK Phosphorylation Assay Kit is based on competitive inhibition of deoxyinosine (dIR) phosphorylation by dCK enzyme. In the absence of nucleoside competitor, deoxycytidine kinase phosphorylates deoxyinosine resulting in the formation of dIMP. dIMP is further oxidized by IMPDH to dXMP and NADH2 continuously monitored at 340nm. In the presence of nucleoside competitor, the phosphorylation of deoxyinosine, poor dCK substrate, is inhibited detected as a decrease in NADH2 formation.

dCK phosphorylation kit reaction schema

PRECICE® dCK Phosphorylation Assay Kit

Ref. #K0307-01
#REF SIZE PRICE
#K0307-01 1 plate (96 assays) 420.00 € Inquiry

Updated on October 3rd, 2024.

Kit is provided in stable lyophilized form and shipped without dry ice

Screening service by NOVOCIB also available
For HTS evaluation of dCK activity in lysates, NOVOCIB offers dCK Assay Kit

Download dCK Phosphorylation Assay protocol (User manual)

Validated with anticancer nucleoside analogues

Such as gemcitabine, cladribine, aracytidine, efficiently phosphorylated by tumor cells and natural pyrimidine and purine nucleosides.

Nucleoside Analogues Deoxycytidine Cladribine Aracytidine Gemcitabine Fludarabine Deoxyguanosine
IC50
(Competitive Inhibition)
5µM 30µM 30µM 100µM 400µM 1,2mM

Simple

Homogenous and continuous (add-and-measure)

High-Throughput Analysis

The assay allows the test of 12 analogues at 7 different concentrations at the same time (or 6 analogues in duplicata)

Readout is peformed with plate reader fitted with 340nm filter

Scientific Articles citing Dck Phosphorylation Assay Kit from NOVOCIB:
  1. Disparate Effects of Cytotoxic Chemotherapy on the Antiviral Activity of Antiretroviral Therapy: Implications for Treatments of HIV-Infected Cancer Patients (2019)
    S. Medina-Moreno, J.C. Zapata, M.L. Cottrell, N.M. Le, S. Tao, J. Bryant, E. Sausville, R.F. Schinazi, A.D.M. Kashuba, R.R Redfield, A. Heredia* Antivir Ther. 2019; 24(3): 17-186.
  2. Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase (2017)
    P.C. Jordan, S.K. Stevens, Y.Tam, R.P. Pemberton, S.Chaudhuri, A.D. Stoycheva, N. Dyatkina, G.Wang, J.A. Symons, J. Deval, L. Beigelman ACS Chem. Biol. 2017, 12, 1, 83-91
  3. Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways (2018) Brand et al., Cell Chemical Biology 25, 1095-1106
    S. Brand, S. Roy, P. Schröder, B. Rathmer, J. Roos, S. Kapoor , S. Patil, C. Pommerenke , T. Maier, P. Janning , S. Eberth, D. Steinhilber, D. Schade, G. Schneider, K. Kumar, S. Ziegler, H. Waldmann
  4. N (4)-[B-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)methyl]-2'-deoxycytidine as a potential boron delivery agent with respect to glioblastoma (2017)
    Ł. Uram , J. Nizioł, P. Maj, J. Sobich , W. Rode, T. Ruman Biomedicine & Pharmacotherapy V. 95, Pages 749-755
  5. Rational Design of an Orally Active Anticancer Fluoropyrimidine, Pencitabine, a Hybrid of Capecitabine and Gemcitabine (2022)
    Thomas I. Kalman ACS Med Chem Lett. 13(3): 409-416